Hapvida: revenue up 3.9%, but adjusted EBITDA falls 33.5% on higher claims
Hapvida's third-quarter 2026 revenue rose 3.9%, but higher medical claims and civil contingencies cut adjusted EBITDA by a third, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Hapvida's third-quarter 2026 revenue climbed 3.9% year on year to R$8.08 billion. However, adjusted EBITDA fell 33.5% as the cash medical loss ratio rose to 77.2%, reflecting seasonality and costs tied to civil contingencies.
According to TradingView, the company reduced its beneficiary base by 235,000 after contract reviews. Net debt declined by R$100.9 million from the previous quarter. The source notes that its text is an AI-generated summary, so readers should verify key figures against the original filing.
why it matters
For investors, the key signal is margin pressure: medical costs are growing faster than revenue, which hits profitability in the insurance business. The smaller member base and lower debt suggest the company is reshaping its portfolio and financial load at the same time.
market impact
Hapvida: rising medical claims pressure EBITDA and margins
- Hapvida shares pressure down — lower adjusted EBITDA and a higher claims ratio weigh on profitability
tags
instruments
sources
- Hapvida Participacoes e Investimentos: Revenue rose, but higher claims and contingencies cut adjusted EBITDA by 33.5% YoY — TradingView, 11 November 2026 at 22:49 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗